Evommune, Inc.
EVMN
$18.87
-$0.02-0.11%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Net Income | 21.62% | 50.46% | -422.88% | ||
| Total Depreciation and Amortization | -6.04% | 15.38% | 39.11% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -36.36% | -14,004.84% | 251.55% | ||
| Change in Net Operating Assets | 123.14% | -123.11% | -362.11% | ||
| Cash from Operations | 63.26% | -203.83% | -394.80% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -352.60% | 79.19% | 38.92% | ||
| Cash from Investing | -353.99% | 79.52% | 39.93% | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -19.30% | -43.52% | -148.39% | ||
| Issuance of Common Stock | -- | -- | 0.00% | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -140.35% | 59,675.00% | -153.33% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -99.75% | 4,241.30% | -321.75% | ||